Navigation Links
Boston to Host 3 Major Annual Drug Discovery Conferences, Early Bird Expiring April 27
Date:4/9/2012

FARMINGTON, Conn., April 9, 2012 /PRNewswire-iReach/ -- Global Information, Inc. is excited to announce remaining available registration for 3 significant Drug Discovery and Healthcare conferences scheduled for Boston, MA in the Spring of 2012.

CHI and Bio-IT World's 12th Annual Structure-Based Drug Design Conference

June 6 - 8, 2012: Structure-based drug design took nearly two decades to arrive at its current mainstream position in medicinal chemistry, and the CHI and Bio-IT World's 12th Annual Structure-Based Drug Design Conference in Cambridge, MA will host an accomplished faculty of experts to focus on recent advancements in this ever evolving, dynamic field. With the crisis facing the pharmaceutical industry in the translation of early stage drug discovery results, a different set of tools concerned with algorithms and methods for developing best-in-class drugs will need to be refined. Join hundreds of colleagues at this excellent once-a-year opportunity to network and share experiences and intelligence.

Save $200 by registering before April 27. Additional information and Early Bird discounted rates at http://www.giiconference.com/chi214654-2012/

Next-Gen Kinase Inhibitors

June 4 - 6, 2012: Explore the exciting question of what lies ahead for the rapidly maturing kinase inhibitors field when pioneers from across the world gather to at the Next-Gen Kinase Inhibitors Conference in Cambridge, MA this June. What is around the corner for the pharmaceutical industry and what new avenues lie ahead for new technologies and methods as novel targets and therapeutic approaches are explored? What ground-breaking kinase indications are being discovered and what other
'/>"/>

SOURCE Global Information, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Boston Scientific Launches Innovative Device Used to Prevent Stone Migration in Urologic Procedures
2. Annual Biotech and Healthcare Conferences Being Held in Boston MA, Summer 2012
3. Boston Scientific Announces Launch of PROMUS Element™ Platinum Chromium Stent System in Japan
4. Cadence Pharmaceuticals CEO Ted Schroeder to Present at the Cowen and Company 32nd Annual Health Care Conference in Boston on March 7, 2012
5. Boston Scientific Announces First Implants of TELIGEN® Implantable Defibrillator in China
6. Boston Scientific Receives Industrys First FDA Approval for Drug-Eluting Coronary Stent Use in Heart Attack Patients
7. Boston Scientific Launches Innovative Crossing Device to Treat Complete Blockages in Peripheral Arteries
8. Boston Scientific to Participate in Leerink Swann 2012 Global Healthcare Conference
9. Boston Scientific Announces First Implant and Market Launch of PROMUS Element™ Plus Stent System in Europe
10. Boston IVF Pioneers Worlds First Needle-Free Saliva Test Used in Infertility Treatment; Patient Friendly Monitoring Replaces Daily Blood Tests
11. Boston Scientific Announces Favorable Ruling in Patent Infringement Case
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... CAMBRIDGE, Mass. , Jan. 15, 2014  Zafgen, ... the unmet needs of severely obese patients, today ... of beloranib, a selective inhibitor of methionine aminopeptidase ... a severe form of genetic obesity.  These results ...
(Date:1/14/2014)... Jan. 14, 2014  Luminex Corporation (Nasdaq: LMNX ) ... fourth quarter of 2013 on Monday, February 3, 2014. A ... the close of trading. (Logo: http://photos.prnewswire.com/prnh/20100104/LUMINEXLOGO ... discuss the operating highlights and financial results for the fourth ...
(Date:1/14/2014)... Healthcare Services, Inc. ("DHS"), a portfolio company of GMH Ventures ... Equipment, Inc. ("Progressive") of Clarion, PA ... not disclosed. Progressive is a full service ... sleep, mobility, and respiratory products to customers in the western ...
Breaking Medicine Technology:Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 3Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 2Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 3
... 7, 2011 In an address to ... John C. Lechleiter, Ph.D., chairman, president and chief executive ... build a new level of trust between the biopharmaceutical ... can harness innovation to help meet growing health care ...
... 2011 Merit Medical Systems, Inc. (NASDAQ: MMSI ... used primarily in cardiology, radiology and endoscopy, announced today that ... quarter ended June 30, 2011, after the close of the ... will hold its investor conference call on the same day ...
Cached Medicine Technology:Lilly CEO Calls for Improved Dialogue in Germany Between Industry and the Government and Health Care System 2Lilly CEO Calls for Improved Dialogue in Germany Between Industry and the Government and Health Care System 3Lilly CEO Calls for Improved Dialogue in Germany Between Industry and the Government and Health Care System 4
(Date:7/10/2014)... Harbor, NY For decades, health-conscious people around the ... in antioxidants, figuring this was one of the paths ... , Yet clinical trials of antioxidant supplements have repeatedly ... to reduce their cancer risk. Virtually all such ... cancer. In fact, in several trials antioxidant supplementation ...
(Date:7/10/2014)... at sarcomas research group at the Bellvitge Biomedical Research ... have been tested in 19 patients a new therapeutic ... which indicate that the new treatment could stabilize the ... in the British Journal of Cancer ., ... and complex since there are several subtypes. It can ...
(Date:7/10/2014)... a new drug could prove useful in treating small cell ... , Scientists from the Cancer Research UK Manchester Institute, based ... Cancer Research Centre, teamed up with experts at AstraZeneca, as ... drug known as AZD3965 - on small cell lung ... Clinical Cancer Research , also helps identify which patients are ...
(Date:7/9/2014)... WASHINGTON, DC (July 10, 2014) If you think winning ... fun for kids think again: Winning along with other mental ... each of which falls into one of 11 big fun ... that winning is all important when it comes to the ... identify and quantify what goes into this elusive conceptuntil now. ...
(Date:7/9/2014)... of low back pain are not linked to weather ... and precipitation. Findings published in Arthritis Care & ... Rheumatology (ACR), indicate that the risk of low back ... gusts, but was not clinically significant. , According ... low back pain at some point in their life, ...
Breaking Medicine News(10 mins):Health News:How antioxidants can accelerate cancers, and why they don't protect against them 2Health News:New therapeutic combination to slow resistant sarcomas 2Health News:New drug active against most aggressive type of lung cancer cells 2Health News:Being a good sport ranks as the top 'fun' factor in study of youth sports 2Health News:Being a good sport ranks as the top 'fun' factor in study of youth sports 3Health News:Low back pain? Don't blame the weather 2
... in U.S., Canada, study says , FRIDAY, April 16 ... places across the United States and Canada could save ... die of cardiac arrest each year, researchers report. , ... in more limited setting, such as casinos or airports, ...
... Inserting new valve within the valve might help high-risk ... -- If an artificial heart valve derived from a ... implanting a mechanical valve inside the artificial valve could ... and opened, the new valve opens and functions similarly ...
... brain lesions developed in patients taking Lipitor than placebo, ... Cholesterol-lowering statin drugs may slow the progression of multiple ... 81 patients with early-stage MS randomly selected to take ... a placebo. After 12 months of treatment, 55.3 percent ...
... Cardiovascular disease appears to be a major risk factor ... -- People with atrial fibrillation, a form of abnormal heart ... Alzheimer,s disease, a new study finds. , The presence of ... especially among younger patients in the group studied, meaning under ...
... Mo. For seniors, dancing isn,t just for fun; ... by University of Missouri researchers found that participation in ... adults. Improved functionality among seniors can decrease their risk ... as dance-based therapy have the potential to significantly reduce ...
... ... ... Researchers at Drexel University College of Medicine have discovered that a certain type ... critical for cancer growth and movement. When researchers reduced and normalized the levels of this ...
Cached Medicine News:Health News:Public Defibrillators Save Lives 2Health News:Public Defibrillators Save Lives 3Health News:Cholesterol Drugs May Slow MS 2Health News:Abnormal Heart Rhythm Linked to Alzheimer's 2Health News:Abnormal Heart Rhythm Linked to Alzheimer's 3Health News:Dance therapy improves seniors' gait, balance, researcher finds 2Health News:Scientists Report Key Finding in Breast Cancer Research 2Health News:Scientists Report Key Finding in Breast Cancer Research 3
Non-Illuminated Trial Lens Set is an attractive set of trial lenses worked to a high standard of accuracy....
Trial Lens Sets....
... disc test (P/N LD15C) include a durable ... instructions. P/N LD15C also includes a Plexiglas ... covers for the test subjects fingers ( ... color discs). Beware that these finger cots ...
Opti-Free Express multi-purpose disinfecting solution lasting comfort No Rub formula provides triple action protection for your contact lenses....
Medicine Products: